Therapeutic Effect of Botulinum Toxin-A in 88 Patients with Trigeminal Neuralgia with 14-month Follow-up

Overview

Journal J Headache Pain

Publisher Biomed Central

Date 2014 Jun 23

PMID 24952600

Citations 17

Authors

Shuang Li

Ya-Jun Lian

Yuan Chen

Hai-Feng Zhang

Yun-Qing Ma

Cai-Hong He

Chuan-Jie Wu

Nan-Chang Xie

Ya-Ke Zheng

Yi Zhang

Affiliations

Soon will be listed here.

Abstract

Background: We investigated the long-term effects and safety of botulinum toxin-A (BTX-A) for treating trigeminal neuralgia (TN). We also studied long-term maintenance of this therapeutic effect.

Methods: A visual analog scale (VAS) score, pain attack frequency per day, patient's overall response to treatment and side effects during 14-month follow-up were evaluated in 88 patients with TN receiving BTX-A. The primary endpoints were pain severity (assessed by VAS) and pain attack frequency per day. The secondary endpoint was the patient's overall response to treatment, assessed using the Patient Global Impression of Change. The influence of different doses (≤50, 50-100 and ≥100 U) on the therapeutic effect was evaluated.

Results: Treatment was deemed "effective" within 1 month in 81 patients and at 2 months in 88 patients (100%). The shortest period of effective treatment was 3 months, and complete control of pain was observed in a maximum of 46 patients. The therapeutic effect decreased gradually after 3 months, and the prevalence of effective treatment at 14 months was 38.6%, with complete control of pain seen in 22 patients (25%). There was no significant difference in the prevalence of effective treatment between different dose groups at identical time points (p > 0.05). Three patients showed swelling at injection sites and 10 patients showed facial asymmetry, both of which disappeared spontaneously without special treatment.

Conclusion: Local subcutaneous injection of BTX-A for TN treatment has considerable therapeutic effects lasting several months and is safe for this indication. At least one-quarter of patients maintained complete analgesia. The maintenance period of the therapeutic effect may be related to the reduction in the VAS score after the first injection of BTX-A.

Citing Articles

Botulinum Toxin Type A for Trigeminal Neuralgia: A Comprehensive Literature Review.

Tereshko Y, Dal Bello S, Lettieri C, Belgrado E, Gigli G, Merlino G Toxins (Basel). 2024; 16(11).

PMID: 39591255 PMC: 11597931. DOI: 10.3390/toxins16110500.

Non-Migraine Head Pain and Botulinum Toxin.

Farham F, Onan D, Martelletti P Toxins (Basel). 2024; 16(10).

PMID: 39453207 PMC: 11511419. DOI: 10.3390/toxins16100431.

Compared to oxcarbazepine and carbamazepine, botulinum toxin type A is a useful therapeutic option for trigeminal neuralgia symptoms: A systematic review.

Naderi Y, Rad M, Sadatmoosavi A, Khaleghi E, Khorrami Z, Chamani G Clin Exp Dent Res. 2024; 10(2):e882.

PMID: 38558383 PMC: 10982606. DOI: 10.1002/cre2.882.

Single OnabotulinumtoxinA Session Add-On to Carbamazepine or Oxcarbazepine in Treatment-Refractory Trigeminal Neuralgia: A Case Series with 24-Week Follow Up.

Xiromerisiou G, Lampropoulos I, Dermitzakis E, Vikelis M, Marogianni C, Mysiris D Toxins (Basel). 2023; 15(9).

PMID: 37755965 PMC: 10534438. DOI: 10.3390/toxins15090539.

Non-Surgical Treatments of Trigeminal Neuralgia from the Perspective of a Pain Physician: A Narrative Review.

Lee J, Lee G, Yi S, Sim W, Kim B, Park H Biomedicines. 2023; 11(8).

PMID: 37626811 PMC: 10452234. DOI: 10.3390/biomedicines11082315.

References

Wu C, Lian Y, Zheng Y, Zhang H, Chen Y, Xie N . Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial. Cephalalgia. 2012; 32(6):443-50. DOI: 10.1177/0333102412441721. View

Fabregat G, De Andres J, Villanueva-Perez V, Asensio-Samper J . Subcutaneous and perineural botulinum toxin type a for neuropathic pain: a descriptive review. Clin J Pain. 2013; 29(11):1006-12. DOI: 10.1097/AJP.0b013e31827eafff. View

Yuan R, Sheu J, Yu J, Chen W, Tseng I, Chang H . Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology. 2009; 72(17):1473-8. DOI: 10.1212/01.wnl.0000345968.05959.cf. View

Turk U, Ilhan S, Alp R, Sur H . Botulinum toxin and intractable trigeminal neuralgia. Clin Neuropharmacol. 2005; 28(4):161-2. DOI: 10.1097/01.wnf.0000172497.24770.b0. View

Borodic G, Acquadro M . The use of botulinum toxin for the treatment of chronic facial pain. J Pain. 2003; 3(1):21-7. DOI: 10.1054/jpai.2002.27142. View

Zuniga C, Diaz S, Piedimonte F, Micheli F . Beneficial effects of botulinum toxin type A in trigeminal neuralgia. Arq Neuropsiquiatr. 2008; 66(3A):500-3. DOI: 10.1590/s0004-282x2008000400012. View

Gazerani P, Pedersen N, Staahl C, Drewes A, Arendt-Nielsen L . Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain. 2008; 141(1-2):60-9. DOI: 10.1016/j.pain.2008.10.005. View

Woolf C, Costigan M . Transcriptional and posttranslational plasticity and the generation of inflammatory pain. Proc Natl Acad Sci U S A. 1999; 96(14):7723-30. PMC: 33609. DOI: 10.1073/pnas.96.14.7723. View

Micheli F, Scorticati M, Raina G . Beneficial effects of botulinum toxin type a for patients with painful tic convulsif. Clin Neuropharmacol. 2002; 25(5):260-2. DOI: 10.1097/00002826-200209000-00006. View

10.

Bowen M, Weninger K, Brunger A, Chu S . Single molecule observation of liposome-bilayer fusion thermally induced by soluble N-ethyl maleimide sensitive-factor attachment protein receptors (SNAREs). Biophys J. 2004; 87(5):3569-84. PMC: 1304822. DOI: 10.1529/biophysj.104.048637. View

11.

Bohluli B, Motamedi M, Bagheri S, Bayat M, Lassemi E, Navi F . Use of botulinum toxin A for drug-refractory trigeminal neuralgia: preliminary report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010; 111(1):47-50. DOI: 10.1016/j.tripleo.2010.04.043. View

12.

Hall G, Carroll D, Parry D, McQuay H . Epidemiology and treatment of neuropathic pain: the UK primary care perspective. Pain. 2006; 122(1-2):156-62. DOI: 10.1016/j.pain.2006.01.030. View

13.

Taylor M, Silva S, Cottrell C . Botulinum toxin type-A (BOTOX) in the treatment of occipital neuralgia: a pilot study. Headache. 2008; 48(10):1476-81. DOI: 10.1111/j.1526-4610.2008.01089.x. View

14.

Aoki K . Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology. 2005; 26(5):785-93. DOI: 10.1016/j.neuro.2005.01.017. View

15.

Meng J, Ovsepian S, Wang J, Pickering M, Sasse A, Aoki K . Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. J Neurosci. 2009; 29(15):4981-92. PMC: 6665337. DOI: 10.1523/JNEUROSCI.5490-08.2009. View

16.

Xiao L, Mackey S, Hui H, Xong D, Zhang Q, Zhang D . Subcutaneous injection of botulinum toxin a is beneficial in postherpetic neuralgia. Pain Med. 2010; 11(12):1827-33. DOI: 10.1111/j.1526-4637.2010.01003.x. View